A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.

被引：0
|
作者：
Chu, Quincy S.
Sangha, Randeep S.
Hotte, Sebastien J.
Sergenson, Gwen
Chand, Vikram K.
Sufan, Roxana
Gu, Yu
Schnell, David
Hirte, Hal W.
机构：
[1] Cross Canc Ctr, Edmonton, AB, Canada
[2] Juravinski Canc Ctr, Hamilton, ON, Canada
[3] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA
[4] Boehringer Ingelheim Canada Ltd, Burlington, ON, Canada
[5] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2523
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors
    Quincy S. Chu
    Randeep Sangha
    Sebastien J. Hotte
    Gwen Sergenson
    David Schnell
    Vikram K. Chand
    Hal W. Hirte
    Investigational New Drugs, 2014, 32 : 1226 - 1235
  • [2] A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors
    Chu, Quincy S.
    Sangha, Randeep
    Hotte, Sebastien J.
    Sergenson, Gwen
    Schnell, David
    Chand, Vikram K.
    Hirte, Hal W.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1226 - 1235
  • [3] Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial.
    Chu, Quincy
    Sangha, Randeep
    Hotte, Sebastien J.
    Deng, Qiqi
    Gyorffy, Steve
    Chand, Vikram K.
    Hirte, Hal W.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors
    Gordon, Michael S.
    Springett, Gregory M.
    Su, Yungpo Bernard
    Ould-Kaci, Mahmoud
    Wind, Sven
    Zhao, Yihua
    LoRusso, Patricia M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1479 - 1491
  • [5] Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study
    Normand Blais
    D. Ross Camidge
    Derek J. Jonker
    Denis Soulières
    Scott A. Laurie
    Sami G. Diab
    Ana Ruiz-Garcia
    Aron Thall
    Ke Zhang
    Richard C. Chao
    Laura Q. Chow
    Investigational New Drugs, 2013, 31 : 1487 - 1498
  • [6] Phase I dose-escalation trial evaluating the safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors
    Awada, A.
    Gil, T.
    Whenham, N.
    Vanhamme, J.
    Mancini, I.
    Besse, T.
    Brendel, E.
    Loembe, B.
    Piccart, M.
    Hendlisz, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 39 - 39
  • [7] A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
    de Braud, F.
    Cascinu, S.
    Spitaleri, G.
    Pilz, K.
    Clementi, L.
    Liu, D.
    Sikken, P.
    De Pas, T.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2341 - 2346
  • [8] Phase I dose escalation trial of biweekly pemetrexed in combination with docetaxel in advanced solid tumors
    Garland, L. L.
    Cranmer, L., III
    Gerstner, G.
    Walker, R.
    Obregon, Y.
    Ebbinghaus, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] A phase I dose-escalation and pk study of continuous oral rucaparib in patients with advanced solid tumors
    Flynn, M.
    Shapiro, G.
    LoRusso, P.
    Kristeleit, R.
    Patel, M.
    Infante, J.
    Giordano, H.
    Borrow, J.
    Jaw-Tsai, S.
    Burris, H., III
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S185
  • [10] Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies-results of a phase I dose-escalation study
    Blais, Normand
    Camidge, D. Ross
    Jonker, Derek J.
    Soulieres, Denis
    Laurie, Scott A.
    Diab, Sami G.
    Ruiz-Garcia, Ana
    Thall, Aron
    Zhang, Ke
    Chao, Richard C.
    Chow, Laura Q.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1487 - 1498
12345